Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, . . . Linda Stein-Gold. (2024). Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. Taylor & Francis Group.
Chicago Style (17th ed.) CitationJennifer Soung, et al. Lebrikizumab Monotherapy Impacts on Quality of Life Scores Through Improved Itch and Sleep Interference in Two Phase 3 Trials. Taylor & Francis Group, 2024.
MLA (9th ed.) CitationJennifer Soung, et al. Lebrikizumab Monotherapy Impacts on Quality of Life Scores Through Improved Itch and Sleep Interference in Two Phase 3 Trials. Taylor & Francis Group, 2024.
Warning: These citations may not always be 100% accurate.